- Home
- ALXO
as 07-26-2024 4:00pm EST
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 358.4M | IPO Year: | 2020 |
| Target Price: | $20.50 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.71 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.94 - $17.83 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of ALX Oncology Holdings Inc. (ALXO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Pons Jaume | ALXO | PRESIDENT & CSO | Jul 11 '24 | Sell | $7.90 | 20,000 | $158,076.00 | 593,447 | SEC Form 4 |
| Pinto Shelly | ALXO | SVP, FINANCE AND CAO | Jul 5 '24 | Sell | $5.50 | 1,823 | $10,025.22 | 92,113 | SEC Form 4 |
| Randolph Sophia | ALXO | CHIEF MEDICAL OFFICER | Jul 1 '24 | Sell | $5.82 | 3,273 | $19,044.93 | 327,076 | SEC Form 4 |
| Pons Jaume | ALXO | PRESIDENT & CSO | Jul 1 '24 | Sell | $5.82 | 10,758 | $62,598.65 | 593,447 | SEC Form 4 |
| Pinto Shelly | ALXO | SVP, FINANCE AND CAO | Jul 1 '24 | Sell | $5.82 | 1,373 | $7,989.21 | 93,936 | SEC Form 4 |
| GARCIA PETER S | ALXO | CHIEF FINANCIAL OFFICER | Jun 13 '24 | Buy | $8.53 | 12,000 | $102,338.40 | 122,348 | SEC Form 4 |
| GARCIA PETER S | ALXO | CHIEF FINANCIAL OFFICER | Jun 13 '24 | Buy | $8.53 | 12,000 | $102,338.40 | 122,348 | SEC Form 4 |
| Pons Jaume | ALXO | PRESIDENT & CSO | Jun 4 '24 | Sell | $8.43 | 20,000 | $168,652.00 | 604,205 | SEC Form 4 |
| Randolph Sophia | ALXO | CHIEF MEDICAL OFFICER | May 13 '24 | Sell | $15.82 | 10,203 | $161,379.83 | 332,146 | SEC Form 4 |
| Randolph Sophia | ALXO | CHIEF MEDICAL OFFICER | May 13 '24 | Sell | $16.67 | 1,797 | $29,958.87 | 330,349 | SEC Form 4 |
| Pons Jaume | ALXO | PRESIDENT & CSO | May 6 '24 | Sell | $15.92 | 20,000 | $318,334.00 | 604,205 | SEC Form 4 |
| Pons Jaume | ALXO | PRESIDENT & CSO | Apr 16 '24 | Sell | $14.20 | 50,000 | $710,195.00 | 604,205 | SEC Form 4 |
| Pons Jaume | ALXO | PRESIDENT & CSO | Apr 4 '24 | Sell | $11.15 | 20,000 | $223,036.00 | 628,359 | SEC Form 4 |
| Lettmann Jason | ALXO | CHIEF EXECUTIVE OFFICER | Mar 14 '24 | Buy | $11.31 | 4,400 | $49,771.48 | 171,620 | SEC Form 4 |
| Pinto Shelly | ALXO | SVP, Finance and CAO | Jan 4 '24 | Sell | $13.60 | 2,717 | $36,956.63 | 78,591 | SEC Form 4 |
| Pons Jaume | ALXO | President & CSO | Dec 29 '23 | Sell | $15.04 | 7,179 | $107,972.16 | 618,359 | SEC Form 4 |
| Pinto Shelly | ALXO | SVP, Finance and CAO | Dec 29 '23 | Sell | $15.04 | 1,631 | $24,530.24 | 81,308 | SEC Form 4 |
| GARCIA PETER S | ALXO | Chief Financial Officer | Dec 29 '23 | Sell | $15.04 | 1,893 | $28,470.72 | 85,348 | SEC Form 4 |
| Randolph Sophia | ALXO | Chief Medical Officer | Dec 29 '23 | Sell | $15.04 | 3,128 | $47,045.12 | 312,349 | SEC Form 4 |
Latest ALX Oncology Holdings Inc. News
ALXO Breaking Stock News: Dive into ALXO Ticker-Specific Updates for Smart Investing
Zacks
17 days ago
IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
Zacks
17 days ago
Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag
Zacks
18 days ago
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
Zacks
21 days ago
Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe
Zacks
22 days ago
Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals
Zacks
23 days ago
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
Zacks
23 days ago
Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study
Zacks
24 days ago
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Compare ALXO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALXO ALX Oncology Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.